Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Regeneron Pharmaceuticals
With
Bayer
Age
50–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Men or women ≥50 years of age with active subfoveal choroidal neovascularization (CNV) secondary to nAMD
Best Corrected Visual Acuity (BCVA) Early Treatment Diabetic Retinopathy Study (ETDRS) letter score of 78 to 24 (Snellen equivalent of 20/32 to 20/320) in the study eye
You may not be if
Evidence of CNV due to any cause other than nAMD in either eye
Evidence of diabetic macular edema (DME) or diabetic retinopathy (defined as more than 1 microaneurysm) in either eye in diabetic patients
Prior use of IVT anti-VEGF agents (aflibercept, ranibizumab, bevacizumab, brolucizumab, pegaptanib sodium) in the study eye
Prior IVT investigational agents in either eye (eg, anti-ang-2/anti-VEGF bispecific monoclonal antibodies, gene therapy)
Previous use of intraocular or periocular corticosteroids within 120 days of screening or treatment with an IVT steroid implant at any time in the study eye
History of vitreoretinal surgery (including scleral buckling) in the study eye
Any other intraocular surgery within 12 weeks (84 days) before the screening visit
History of corneal transplant or corneal dystrophy in study eye
Clareo Health | Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration
